USA flag logo/image

An Official Website of the United States Government

Novel Leukocyte Receptor and Allograft Rejection

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
24799 		Program Year/Program:
1994 / SBIR
Agency Tracking Number:
24799 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Activated Cell Therapy, Inc.
291 N Bernardo Avenue Mountain View, CA 94043
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1994
Title: Novel Leukocyte Receptor and Allograft Rejection
Agency: HHS
Contract: 1 R43 AI36755-1,
Award Amount: $75,000.00
 

Abstract:

We will extend recent observations regarding the discovery and characterization of alloreaction-a-ssociated antigen (ARAg), a novel member of the immunoglobulin gene superfamily selectively expressedon leukocyte subsets. ARAg surface expression is increased on T lymphocytes in response to allogeneic,but not by mitogenic, stimuli and anti-ARAg monoclonal antibody (mAb) P1C5 specifically blocks thisalloactivation response in vitro. There are two aims of this proposal: 1) to provide evidence for theexistence of a putative ARAg counter-receptor (ARAg-CR) expressed which presumably interacts withARAg in transduction of important activation signals, and 2) to isolate a cDNA clone encoding the murinehomologue of ARAg. Soluble recombinant ARAg proteins will be engineered and used in flow cytometryassays to examine phenotypic expression of the putative ARAg-CR on relevant cell types. Evidence forthe existence of a putative ARAg-CR will provide an additional target for potential pharmacologicintervention. Molecular cloning of the murine ARAg homologue is essential for development of an animalmodel in which to evaluate candidate ARAg-based therapeutics in vivo. The long-term objective of thisproject is to develop ARAg-related reagents for their potential therapeutic value in allograft rejection andGVHD as well as autoimmune disease and reperfusion injury.

Principal Investigator:

Curtis Ruegg
4159646744

Business Contact:

Small Business Information at Submission:

Activated Cell Therapy, Inc.
291 N Bernardo Avenue Mountain View, CA 94043

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No